文献速递肾移植

肾移植前CT体成分与移植物丢失的关联:国际观察性研究

Association of Myosteatosis and of Graft Loss after Kidney Transplantation: An International Observational Study.
PubMed 文献 · Clin J Am Soc Nephrol · 2025-10-15

本研究基于两个中心(JHH和UMCG)2003至2020年接受肾移植的成人受者,利用移植前CT评估骨骼肌减少和肌肉脂肪变性,分析其与全因移植物丢失和死亡的关系。结果显示肌肉脂肪变性与JHH队列的全因移植物丢失和死亡风险升高相关,但在UMCG队列无显著关联;骨骼肌减少与结局无关。

要点

  • 移植前肌肉脂肪变性与全因移植物丢失和死亡风险升高相关(JHH队列)。
  • 骨骼肌减少与移植后全因移植物丢失或死亡无显著关联。
  • 肌肉脂肪变性与死亡删失的移植物丢失无显著关联。

核心结论

  • 肌肉脂肪变性可识别全因移植物丢失高风险受者,可能从预康复中获益。

研究设计与样本

  • 国际多中心观察性研究,纳入JHH 294例和UMCG 314例成人肾移植受者,随访中位时间分别为6.4年和6.3年。

主要发现

  • JHH队列中肌肉脂肪变性与全因移植物丢失风险升高相关(校正HR 1.78,95%CI 1.08-2.93)。
  • JHH队列中肌肉脂肪变性与死亡风险升高相关(校正HR 2.35,95%CI 1.27-4.33)。
  • UMCG队列中肌肉脂肪变性与上述结局无显著关联。
  • 两中心肌肉脂肪变性与死亡删失的移植物丢失均无显著关联。
  • 骨骼肌减少与全因移植物丢失或死亡无显著关联。

关键数值与推荐

  • 移植前49%受者存在骨骼肌减少,66%存在肌肉脂肪变性。

临床怎么用

  • 可利用现有CT评估肌肉脂肪变性,识别全因移植物丢失高风险受者并考虑预康复。

局限性

  • 两中心结果不一致,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Myosteatosis was associated with a higher risk of all-cause graft loss and mortality within the US cohort. Myosteatosis did not show an higher risk of death censored graft loss at both centers. Sarcopenia was not associated with a higher risk of all-cause graft loss or mortality. BACKGROUND: Sarcopenia and myosteatosis are indicators of abnormal body composition (BC). Computed tomography (CT) imaging has proven to be an accurate modality for BC quantification in kidney transplantation (KT). We tested whether pre-KT CT-based BC was associated with both all-cause graft loss (ACGL) and mortality among adult recipients from two centers (Johns Hopkins Hospital [JHH] and University Medical Center Groningen [UMCG]). METHODS: Patients who underwent a KT between 2003 and 2020 were followed for a median (interquartile range) follow-up of 6.4 (4.6–8.5) years at JHH and 6.3 (5.1–7.5) years at UMCG. Cox proportional hazard models were used to estimate the associations of BC with ACGL/mortality. Fine and Gray regression analysis was performed to assess the association between BC and death-censored graft loss. Before KT, 49% of recipients had sarcopenia and 66% had myosteatosis. RESULTS: In total, 608 patients were included from JHH ( N =294) and UMCG ( N =314). Sarcopenia was not associated with post-KT outcomes. Myosteatosis was associated with a higher risk of ACGL (adjusted hazard ratio, 1.78; 95% confidence interval, 1.08 to 2.93) and mortality (adjusted hazard ratio, 2.35; 95% confidence interval, 1.27 to 4.33) at JHH but showed no significant association at UMCG after adjusting for confounders. Myosteatosis did not show a significant association with death-censored graft loss at both centers. CONCLUSIONS: Myosteatosis ascertained from existing CT scans could help identify recipients at higher risk for ACGL who may benefit most from prehabilitation.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Zorgdrager M, Liu Y, Hong J, et al. Association of Myosteatosis and of Graft Loss after Kidney Transplantation: An International Observational Study. Clin J Am Soc Nephrol. 2025. PMID: 41091560. doi:10.2215/CJN.0000000862

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。